This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched

04/07/15 - 08:02 AM EDT

Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.

READ FULL POST

The Top-Performing Biotech Stock During a Sizzling First Quarter

04/01/15 - 09:30 AM EDT

The Top-Performing Biotech Stock During a Sizzling First Quarter That was one crazy first quarter for the biotech sector. Here's where biotech stocks stand on April Fool's Day.

READ FULL POST

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble

03/31/15 - 11:30 AM EDT

Bankrupt Introgen Seeks Reincarnation IPO in Biotech Bubble Will the biotech bubble support the comeback of Introgen Therapeutics, one of the sector's largest disasters?

READ FULL POST

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate

03/30/15 - 10:43 AM EDT

Biotech Merger Monday Doesn't Squash Biotech Bubble Debate Neither of the deals announced Monday are blockbusters or particularly transformative. Both buyers have specific needs and went after small targets for large prices.

READ FULL POST

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company

03/24/15 - 10:39 AM EDT

PTC Therapeutics CEO Liquidates Stock Ownership in His Own Company Biotech CEOs are supposed to be cheerleaders for their stock, so it's noteworthy when a CEO's pocketbook indicates otherwise.

READ FULL POST

Celgene's Crohn's Disease Drug Candidate Highlighted in NEJM

03/18/15 - 05:00 PM EDT

Celgene's Crohn's Disease Drug Candidate Highlighted in NEJM Celgene will be starting phase III studies of mongersen in Crohn's disease -- designed to lead to the drug's approval -- by the middle of the year.

READ FULL POST

Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals

03/17/15 - 10:26 AM EDT

Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals When a biotech CEO diverts from safe, bland corporate tweets to engage in some clever competitive trolling, I stand and applaud.

READ FULL POST

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

03/13/15 - 09:36 AM EDT

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.

READ FULL POST

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio?

03/11/15 - 10:45 AM EDT

U.K. Regulators Grant Early Access to Merck Skin Cancer Drug, but Where Is Northwest Bio? Skin cancer patients in Britain can be treated with Merck's Keytruda before the cancer immunotherapy drug is approved there under a new early access plan announced Wednesday.

READ FULL POST

Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear

03/10/15 - 10:17 AM EDT

Ocular Therapeutix Eye-Pain Plug Benefits Still Unclear Ocular hasn't conducted clinical trials that would demonstrate that OTX-DP is any better than eye drops in reducing swelling and pain in the eye.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Adam's Tweets

Top Rated Stocks Top Rated Funds Top Rated ETFs